Neuropathy is very common, and it’s estimated that at least 8% of the world's population has it. The United States alone has over 40 million people suffering from neuropathy, and their associated health costs exceed $4 billion annually. Presently, over 50% of diabetics, 20% of cancer patients undergoing chemotherapy and at least 10% of the US population 40 years and older will be diagnosed with neuropathy.
We are working to prevent and reverse nerve damage associated with peripheral neuropathy through the repair and regrowth of peripheral nerves. Our results validate the discovery of a pathway to regenerate peripheral nerves and reduce symptoms associated with peripheral nerve damage.
Who We Are:
+ Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors
We have one mission—impact patients’ lives. We follow the science to lead us to this goal. Currently, we are focused on managing global resources to accelerate the development of potentially disease-modifying treatments for patients with peripheral neuropathy.
While diabetes is the leading cause of peripheral neuropathy, neurological disorders like GBS and CIDP may also be the culprit. GBS and CIDP-related peripheral neuropathy are more common in older
What causes sleep issues for people with diabetes? Sleep issues are prevalent among
WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.
